ArticleNature methods2024
Closing in on cancer heterogeneity with organoids.
Article in Nature methods, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Organoids: From Bench to Bedside Applications.MedComm · 2026Review
- The heterogeneity of dermal mesenchymal cells reproduced in skin equivalents regulates barrier function and elasticity.EMBO reports · 2026Article
- Harnessing Cancer Stem Cells and 3D Organoids in Unravelling Spatial and Cellular Heterogeneity in Cancer.International journal of molecular sciences · 2026Review
- Microgravity-cultured glioblastoma organoids integrated with microfluidic chip for CAR-γδ T evaluation.Communications biology · 2025Article
- Reprogramming neural-tumor crosstalk: emerging therapeutic dimensions and targeting strategies.Military Medical Research · 2025Review
- Unraveling the Clinical Landscape of RNA Modification Regulators with Multi-Omics Insights in Pan-Cancer.Cancers · 2025Article
- Digitalized organoids: integrated pipeline for high-speed 3D analysis of organoid structures using multilevel segmentation and cellular topology.Nature methods · 2025Article
- 3D tumor cultures for drug resistance and screening development in clinical applications.Molecular cancer · 2025Review
- WD40 Protein NLE1 as a Novel Diagnostic Biomarker Promoting Hepatocellular Carcinoma Proliferation.Clinical Medicine Insights. Oncology · 2025Article
- Personalized Treatment for Invasive Ductal Breast Carcinoma with Lung and Liver Metastases Based on Patient-Derived Organoids: A Case Report.OncoTargets and therapy · 2025Article
- Development and Application of Tumor Organoids: An Emerging Platform for Gynecological Cancers.International journal of women's health · 2025Review
- Advancing cancer research through organoid technology.Journal of translational medicine · 2024Review
- Photodynamic Therapy for Oral Squamous Cell Carcinoma: Current Status, Challenges, and Prospects.International journal of nanomedicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
38528185What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.